T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the clinical efficacy and safety of trastuzumab plus
XELOX for treatment of HER2-positive Stage III Gastric Cancer After D2 Gastrectomy.